ATE288765T1 - Polypeptidzusammensetzungen mit verbesserter stabilität - Google Patents

Polypeptidzusammensetzungen mit verbesserter stabilität

Info

Publication number
ATE288765T1
ATE288765T1 AT00983782T AT00983782T ATE288765T1 AT E288765 T1 ATE288765 T1 AT E288765T1 AT 00983782 T AT00983782 T AT 00983782T AT 00983782 T AT00983782 T AT 00983782T AT E288765 T1 ATE288765 T1 AT E288765T1
Authority
AT
Austria
Prior art keywords
glycerin
compositions
polypeptide
chemical stability
improved stability
Prior art date
Application number
AT00983782T
Other languages
English (en)
Inventor
Michael Rosario Defelippis
Michael Allen Dobbins
Alby David Sharknas
Alex Mark Prokai
Joseph Vincent Jun Rinella
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27341882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE288765(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from JP37720899A external-priority patent/JP2001181203A/ja
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE288765T1 publication Critical patent/ATE288765T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AT00983782T 1999-12-16 2000-12-05 Polypeptidzusammensetzungen mit verbesserter stabilität ATE288765T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17113599P 1999-12-16 1999-12-16
JP37720899A JP2001181203A (ja) 1999-12-16 1999-12-28 安定性が改良されたポリペプチド組成物
US18103000P 2000-02-08 2000-02-08
PCT/US2000/032421 WO2001043762A2 (en) 1999-12-16 2000-12-05 Polypeptide compositions with improved stability

Publications (1)

Publication Number Publication Date
ATE288765T1 true ATE288765T1 (de) 2005-02-15

Family

ID=27341882

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00983782T ATE288765T1 (de) 1999-12-16 2000-12-05 Polypeptidzusammensetzungen mit verbesserter stabilität

Country Status (15)

Country Link
EP (1) EP1242121B1 (de)
JP (1) JP2003523972A (de)
CN (1) CN1409640A (de)
AT (1) ATE288765T1 (de)
AU (1) AU777570B2 (de)
BR (1) BR0016334A (de)
CA (1) CA2394213A1 (de)
DE (2) DE60018105T2 (de)
DK (1) DK200000375U1 (de)
EA (1) EA004631B1 (de)
ES (1) ES2236010T3 (de)
IL (1) IL150129A0 (de)
PL (1) PL355378A1 (de)
PT (1) PT1242121E (de)
WO (1) WO2001043762A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60224284T2 (de) 2001-06-28 2008-12-18 Novo Nordisk A/S Stabile formulierung von modifiziertem glp-1
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
WO2004034975A2 (en) * 2002-10-17 2004-04-29 Alkermes Controlled Therapeutics, Inc. Sustained release profile modification
AU2003301654A1 (en) * 2002-10-22 2004-05-13 Dainippon Pharmaceutical Co., Ltd. Stabilized composition
CN102940879B (zh) 2003-06-03 2017-06-06 诺沃挪第克公司 稳定化的药物肽组合物
WO2004105790A1 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
CN104826116A (zh) 2003-11-20 2015-08-12 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
KR101009858B1 (ko) 2003-11-20 2011-01-19 솔베이(소시에떼아노님) 유기 화합물의 제조 방법
ES2442223T3 (es) 2004-08-31 2014-02-10 Novo Nordisk A/S Uso de tris(hidroximetil) aminometano para la estabilización de péptidos, polipéptidos y proteínas
CN106137952B (zh) 2004-11-12 2020-11-17 诺和诺德公司 促胰岛素肽的稳定制剂
DK1884507T3 (da) * 2006-07-27 2010-08-16 Cognis Ip Man Gmbh Fremgangsmåde til fremstilling af glycerol
TWI478875B (zh) 2008-01-31 2015-04-01 Solvay 使水性組成物中之有機物質降解之方法
WO2009115469A1 (en) 2008-03-18 2009-09-24 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
FR2935968B1 (fr) 2008-09-12 2010-09-10 Solvay Procede pour la purification de chlorure d'hydrogene
WO2010043566A2 (de) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Kombination von einem insulin und einem glp-1-agonisten
ES2855146T3 (es) 2009-11-13 2021-09-23 Sanofi Aventis Deutschland Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
US9707176B2 (en) 2009-11-13 2017-07-18 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
JP2011195557A (ja) * 2010-02-24 2011-10-06 Kyorin Pharmaceutical Co Ltd 糖アルコールの選択方法
PT2611458T (pt) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
DK2433651T3 (da) 2010-09-03 2013-04-08 Aug Hedinger Gmbh & Co Kg Fremgangsmåde til bestemmelse af aldehyder og ketoner i glycerin
KR20140009163A (ko) 2010-09-30 2014-01-22 솔베이(소시에떼아노님) 천연유래 에피클로로히드린의 유도체
US9097692B2 (en) 2010-10-01 2015-08-04 Aug. Hedinger Gmbh & Co. Kg Method for quantitatively determining impurities in glycerin
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PT2750699E (pt) 2011-08-29 2015-11-03 Sanofi Aventis Deutschland Acelerómetro pendular
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2013153000A2 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
HUE055231T2 (hu) 2016-12-16 2021-11-29 Novo Nordisk As Inzulint tartalmazó gyógyászati készítmények
TWI762706B (zh) 2017-08-24 2022-05-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
WO2021113136A1 (en) * 2019-12-06 2021-06-10 Dr. Mary Morris & Associates, Llc Methods and compositions for the treatment and prevention of type 1 diabetes
WO2021144476A1 (en) 2020-02-18 2021-07-22 Novo Nordisk A/S Pharmaceutical formulations
CN116847869A (zh) * 2020-10-08 2023-10-03 美商玛丽莫里斯博士联合有限责任公司 用于治疗和预防1型糖尿病的方法和组合物
WO2024081659A1 (en) * 2022-10-13 2024-04-18 Archer Daniels Midland Company Purification of glycerin as excipient in parenteral pharmaceutical applications

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE208208T1 (de) * 1996-06-20 2001-11-15 Novo Nordisk As Halogenid-enthaltende insulinzubereitungen

Also Published As

Publication number Publication date
DK200000375U1 (da) 2001-03-16
CN1409640A (zh) 2003-04-09
IL150129A0 (en) 2002-12-01
WO2001043762A3 (en) 2002-01-10
PT1242121E (pt) 2005-05-31
AU2049301A (en) 2001-06-25
AU777570B2 (en) 2004-10-21
PL355378A1 (en) 2004-04-19
EA004631B1 (ru) 2004-06-24
EP1242121B1 (de) 2005-02-09
CA2394213A1 (en) 2001-06-21
DE60018105T2 (de) 2005-12-29
ES2236010T3 (es) 2005-07-16
BR0016334A (pt) 2002-09-10
JP2003523972A (ja) 2003-08-12
EP1242121A2 (de) 2002-09-25
DE20021079U1 (de) 2001-03-22
DE60018105D1 (de) 2005-03-17
WO2001043762A2 (en) 2001-06-21
EA200200684A1 (ru) 2003-02-27

Similar Documents

Publication Publication Date Title
ATE288765T1 (de) Polypeptidzusammensetzungen mit verbesserter stabilität
TR200402703T4 (tr) Çözünür CTLA4 mutantları ve bunların kullanımı.
ES2181006T3 (es) Uso de amidas de acidos de piridil alcanos, piridil alquenos y/o piridil alquinos en el tratamiento de tumores o en inmunosupresion.
SE0002102D0 (sv) Chemical compound
EA200201096A1 (ru) СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИММУНОДЕПРЕССАНТОВ
MY133969A (en) Indoloquinazolinones
WO2001064834A8 (en) Novel nucleic acids and polypeptides
EA200200808A1 (ru) Модифицированные цитокины, предназначенные для применения в терапии рака
RS51478B (sr) Upotreba bradikardijskih supstanci u lečenju miokardnih oboljenja povezanih sa hipertrofijom i nove kombinacije lekova
BR0115121A (pt) Compostos n-((1,2,4)triazoloazinil)tiofenossulfonamida como herbicidas
TR200100273T2 (tr) Enjeksiyon için parasetamol bazlı farmasötik bileşim.
BR9813810B1 (pt) surfactante baseado em um orto éster, a sua preparação e o seu uso.
TR200501541T2 (tr) Leu-hirudinin e.coli ile kültür ortamında ayrışarak üretilmesinin sinyal sekansları
DE60001850T2 (de) Chalcon coumarine
TR200101493T2 (tr) Eletriptan hidrobromid monohidrat
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8
TR200001080T2 (tr) 2 ile ikame edilmiş 1,2-Benisotiyazol türevleri ve bunların serrotonın antagonistleri
SE9802507D0 (sv) Novel salts
FR2843116B1 (fr) Utilisation d'une structure a base de poly(dimethylcetene) et objets comprenant cette structure
TR200401875T2 (tr) Endoparazit öldürücü bileşimler
AU2001218083A1 (en) Ace inhibitor-vasopressin antagonist combinations
TR200102815T1 (tr) Displazili dokunun tespiti için kullanılacak in vivo lekeleme bileşik ve metodları.
IT8919628A0 (it) Apparecchio frigorifero, specialmente armadio frigorifero per uso domestico o similare.
IT1319871B1 (it) Uso degli ultrasuoni al fine di migliorare la conservazione del lattenello stabilimento di produzione.
ITFO20000026U1 (it) Uso degli ultrasuoni al fine di migliorare la conservazione del lattenello stabilimento di produzione.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1242121

Country of ref document: EP

RZN Patent revoked
RZN Patent revoked